KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) EBIT Margin (2020 - 2025)

Ginkgo Bioworks Holdings' EBIT Margin history spans 6 years, with the latest figure at 211.86% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 2443.0% year-over-year to 211.86%; the TTM value through Dec 2025 reached 185.29%, up 6125.0%, while the annual FY2025 figure was 185.29%, 6125.0% up from the prior year.
  • EBIT Margin reached 211.86% in Q4 2025 per DNA's latest filing, up from 231.78% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 34.37% in Q3 2021 to a low of 1134.55% in Q4 2021.
  • Average EBIT Margin over 5 years is 347.75%, with a median of 235.59% recorded in 2022.
  • Peak YoY movement for EBIT Margin: plummeted -96021bps in 2021, then surged 89966bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 1134.55% in 2021, then skyrocketed by 79bps to 234.89% in 2022, then tumbled by -118bps to 512.49% in 2023, then surged by 54bps to 236.29% in 2024, then grew by 10bps to 211.86% in 2025.
  • Per Business Quant, the three most recent readings for DNA's EBIT Margin are 211.86% (Q4 2025), 231.78% (Q3 2025), and 132.13% (Q2 2025).